Literature DB >> 18726088

Antagonist-precipitated and discontinuation-induced withdrawal in morphine-dependent rhesus monkeys.

G L Becker1, L R Gerak, W Koek, C P France.   

Abstract

RATIONALE: Upon discontinuation of chronic opioid treatment, withdrawal typically peaks in 1-3 days and decreases markedly within 1 week; however, persistent physiological changes have been reported long after other signs have waned.
OBJECTIVE: The goal of this study was to compare the discriminative stimulus, directly observable signs, and physiological effects of withdrawal in morphine-treated monkeys.
MATERIALS AND METHODS: Monkeys received 5.6 mg/kg/12 h morphine and discriminated 0.0178 mg/kg naltrexone while responding under a fixed-ratio 5 schedule of stimulus-shock termination. Drug discrimination, behavioral observation, and telemetry were used to monitor the emergence of withdrawal, as well as any persistent changes, following discontinuation of morphine treatment.
RESULTS: Naltrexone dose (0.001-0.032 mg/kg, s.c.) was positively related with indices of withdrawal. In the discrimination study, monkeys responded on the naltrexone lever 1-5 days following discontinuation of treatment; thereafter, they responded exclusively on the saline lever. After discontinuation of morphine, the frequency of observable signs peaked within 2-3 days and most were not significantly increased after 5 days. In contrast, increased heart rate and body temperature persisted for 14 days, returning to values obtained prior to discontinuation by 21 days.
CONCLUSIONS: To the extent that discriminative stimulus effects of withdrawal in nonhumans are predictive of subjective reports of withdrawal in humans, these data indicate that effective treatments for opioid dependence must address not only the short-term subjective components of withdrawal but also, and perhaps more importantly, lingering behavioral and physiological effects that might contribute to relapse long after chronic drug use is discontinued.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726088      PMCID: PMC3449323          DOI: 10.1007/s00213-008-1293-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

1.  Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine detoxification treatments.

Authors:  Tracy Beswick; David Best; Sian Rees; Jenny Bearn; Michael Gossop; John Strang
Journal:  Addict Biol       Date:  2003-03       Impact factor: 4.280

2.  Thienorphine: receptor binding and behavioral effects in rhesus monkeys.

Authors:  Jun-Xu Li; Ginger L Becker; John R Traynor; Ze-Hui Gong; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2007-01-12       Impact factor: 4.030

3.  Morphine dependence and body temperature in rhesus monkeys.

Authors:  S G Holtzman; J E Villarreal
Journal:  J Pharmacol Exp Ther       Date:  1969-03       Impact factor: 4.030

4.  Physiological parameters of morphine dependence in man--tolerance, early abstinence, protracted abstinence.

Authors:  W R Martin; D R Jasinski
Journal:  J Psychiatr Res       Date:  1969-10       Impact factor: 4.791

5.  Classical conditioning of a morphine abstinence phenomenon, reinforcement of opioid-drinking behavior and "relapse" in morphine-addicted rats.

Authors:  A Wikler; F T Pescor
Journal:  Psychopharmacologia       Date:  1967

6.  Pharmacologic analysis of the hypothermic responses of the morphine-dependent rhesus monkey.

Authors:  S G Holtzman; J E Villarreal
Journal:  J Pharmacol Exp Ther       Date:  1971-05       Impact factor: 4.030

7.  Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys.

Authors:  Stacy L Sell; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

8.  Cocaine and other indirect-acting monoamine agonists differentially attenuate a naltrexone discriminative stimulus in morphine-treated rhesus monkeys.

Authors:  Lance R McMahon; Stacy L Sell; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2003-10-20       Impact factor: 4.030

9.  Low dose of heroin inhibits drug-seeking elicited by cues after prolonged withdrawal from heroin self-administration in rats.

Authors:  Wenhua Zhou; Fuqiang Zhang; Shuaien Tang; Huifen Liu; Miaojun Lai; Guodong Yang
Journal:  Neuroreport       Date:  2004-03-22       Impact factor: 1.837

10.  Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.

Authors:  Sharon L Walsh; Eric C Strain; George E Bigelow
Journal:  Addiction       Date:  2003-04       Impact factor: 6.526

View more
  14 in total

Review 1.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

2.  Drug Discrimination and the Analysis of Private Events.

Authors:  Brian D Kangas; David R Maguire
Journal:  Behav Anal (Wash D C)       Date:  2016-03-14

3.  OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.

Authors:  David R Maguire; Lisa R Gerak; Gerta Cami-Kobeci; Stephen M Husbands; Charles P France; Barbara Belli; Peter Flynn
Journal:  J Pharmacol Exp Ther       Date:  2019-11-20       Impact factor: 4.030

4.  Affective and neuroendocrine effects of withdrawal from chronic, long-acting opiate administration.

Authors:  Kathryn L Hamilton; Andrew C Harris; Jonathan C Gewirtz
Journal:  Brain Res       Date:  2013-09-26       Impact factor: 3.252

5.  Discrimination learning in oxycodone-treated nonhuman primates.

Authors:  Sarah L Withey; Rachel J Doyle; Erica N Porter; Jack Bergman; Brian D Kangas
Journal:  Drug Alcohol Depend       Date:  2019-11-27       Impact factor: 4.492

6.  Effects of daily morphine administration and deprivation on choice and demand for remifentanil and cocaine in rhesus monkeys.

Authors:  Tammy Wade-Galuska; Chad M Galuska; Gail Winger
Journal:  J Exp Anal Behav       Date:  2011-01       Impact factor: 2.468

7.  Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.

Authors:  L R Gerak; C P France
Journal:  J Pharmacol Exp Ther       Date:  2016-03-02       Impact factor: 4.030

8.  Effects of acute and chronic morphine on delay discounting in pigeons.

Authors:  Amy K Eppolito; Charles P France; Lisa R Gerak
Journal:  J Exp Anal Behav       Date:  2013-04-02       Impact factor: 2.468

9.  Effects of Morphine on Behavioral Task Performance in SIV-Infected Rhesus Macaques.

Authors:  Joanne K Marcario; Gurudutt Pendyala; Mariam Riazi; Kandace Fleming; Janet Marquis; Shannon Callen; Steven J Lisco; Stephen C Fowler; Paul D Cheney; Shilpa J Buch
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-02       Impact factor: 4.147

10.  The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys.

Authors:  Colin S Cunningham; Megan J Moerke; Lance R McMahon
Journal:  Behav Pharmacol       Date:  2014-08       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.